xCures
Filipe Dinis has a diverse work experience spanning several roles and industries. Filipe is currently working as the Graphic Design/Social Media Director at xCures since 2022. Prior to this, they worked as a Freelance Graphic Designer at CreativeBuzz starting from 2007. From 2006 to 2021, they served as a Senior Graphic Designer/Marketing Officer at Trans-Fast. During their tenure at Trans-Fast, Filipe played a crucial role in the company's digital transformation, overseeing the design of the website, app, and online forms, as well as managing integration with new technology partners. Before joining Trans-Fast, Filipe worked as a Graphic Designer at AEP - Artes Gráficas from 2004 to 2006. Filipe also founded their own design agency, Benzinadesign, and served as its CEO/Founder from 2001 to 2004.
Filipe Dinis holds a Licentiate degree in Graphic Design from ISDOM. In 2016, they completed a course in Facebook Marketing at FLAG. In 2017, they pursued a course in Anti-Money Laundering and Financial Crime at High Speed Training. In 2018, they obtained a certification in Data Protection from the same institution. Additionally, in 2020, they completed a Google Ads course at FLAG.
This person is not in any teams
This person is not in any offices
xCures
The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, withan AI-based precision oncology platform that tightly integrates cancer research and care.The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives.